Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta‐analysis including 13,146 patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta‐analysis including 13,146 patients
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-02-22
DOI
10.1111/jcpt.13385
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Stabilizing HIF to Ameliorate Anemia
- (2020) Richard A. Voit et al. CELL
- Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia
- (2020) Tadao Akizawa et al. Clinical Journal of the American Society of Nephrology
- Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan
- (2020) Tadao Akizawa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
- (2020) Theo Vos et al. LANCET
- Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
- (2019) Nan Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
- (2019) Nan Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
- (2019) Neil S. Sanghani et al. ADVANCES IN CHRONIC KIDNEY DISEASE
- RoB 2: a revised tool for assessing risk of bias in randomised trials
- (2019) Jonathan A C Sterne et al. BMJ-British Medical Journal
- A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis
- (2019) Christine K. Bailey et al. BMC Nephrology
- The role of hypoxia-inducible factor stabilizers in the treatment of anemia in patients with chronic kidney disease
- (2018) Hongzhen zhong et al. Drug Design Development and Therapy
- Effects of Molidustat in the Treatment of Anemia in CKD
- (2018) Iain C. Macdougall et al. Clinical Journal of the American Society of Nephrology
- Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver
- (2017) Seonghwan Hwang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mechanisms and mediators of hypertension induced by erythropoietin and related molecules
- (2017) Rajiv Agarwal NEPHROLOGY DIALYSIS TRANSPLANTATION
- Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
- (2017) Nan Chen et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Anemia in the elderly: a consequence of aging?
- (2017) Racha Halawi et al. Expert Review of Hematology
- A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial
- (2016) Richard A. Brigandi et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
- (2016) Robert Provenzano et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
- (2016) Tadao Akizawa et al. AMERICAN JOURNAL OF NEPHROLOGY
- Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease
- (2016) Pablo E. Pergola et al. KIDNEY INTERNATIONAL
- Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia
- (2015) L. Holdstock et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
- (2015) Anatole Besarab et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Chronic kidney disease: global dimension and perspectives
- (2013) Vivekanand Jha et al. LANCET
- Anaemia management and mortality risk in chronic kidney disease
- (2013) Walter H. Hörl Nature Reviews Nephrology
- Mechanisms of Anemia in CKD
- (2012) J. L. Babitt et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Timing of Erythropoiesis-Stimulating Agent Initiation and Adverse Outcomes in Nondialysis CKD: a Propensity-Matched Observational Study
- (2010) S. Seliger et al. Clinical Journal of the American Society of Nephrology
- Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes
- (2010) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anemia, Diabetes, and Chronic Kidney Disease
- (2009) U. Mehdi et al. DIABETES CARE
- Erythropoietic stress and anemia in diabetes mellitus
- (2009) Dhruv K. Singh et al. Nature Reviews Endocrinology
- A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
- (2009) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now